Author

Anthony F. Daniyan

Memorial Sloan Kettering Cancer CenterORCID 0009-0002-2742-2281Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:cell-cell communication· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:CITE-seq· 1 Assay:flow cytometry· 1

Frequent Co-Authors

Christopher Austin KlebanoffiD· 2 shared Katharine C. HsuiD· 2 shared Smita S. ChandraniD· 2 shared Aya G. HalawiiD· 1 shared Caleb A. LareauiD· 1 shared Christopher S. HackettiD· 1 shared Clara Lawry· 1 shared Doron BeteliD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Christopher Austin KlebanoffORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologyJournal of Clinical InvestigationPeer-reviewedOct 20, 2026

Engineered NKG2C+ NK-like T cells exhibit superior antitumor efficacy while mitigating cytokine release syndrome

Kyle B. Lupo, M. Kazim Panjwani, Aya G. Halawi…·Katharine C. Hsu

This study shows that engineered NKG2C+ NK-like T cells have better antitumor effects and lower cytokine release syndrome risk than conventional CAR-T and CAR-NK cells.

5 citations

humanCITE-seq

𝕏 PostBluesky

ImmunologyNature CancerPeer-reviewedJul 22, 2025

CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit

Fei Yi, Tal Cohen, Natalie Zimmerman…·Christopher Austin Klebanoff

This study identifies FASLG expression patterns and shows that FAS-L/FAS auto-regulation governs CAR-T and CAR-NK cell persistence, enhancing antitumor efficacy when FAS is inhibited.

55 citationstop 1%

humanscRNA-seq

𝕏 PostBluesky